Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens

Strategies for the management of adverse events associated with mTOR inhibitors

(2014) Bruce Kaplan et al.   Transplantation Reviews

Calcineurin Inhibitor Nephrotoxicity: A Review and Perspective of the Evidence

(2013) Naim Issa et al.   AMERICAN JOURNAL OF NEPHROLOGY

Planned Randomized Conversion From Tacrolimus to Sirolimus-Based Immunosuppressive Regimen inDe NovoKidney Transplant Recipients

(2013) H. T. Silva et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation

(2012) T. Isakova et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation

(2012) Markus Guba et al.   TRANSPLANT INTERNATIONAL

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study

(2011) Y. Lebranchu et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients

(2011) S. M. Flechner et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

(2011) Klemens Budde et al.   LANCET

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

(2011) Liset H. M. Pengel et al.   TRANSPLANT INTERNATIONAL

Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study

(2011) Hallvard Holdaas et al.   TRANSPLANTATION

Lipid Profile Changes During the First Year After Kidney Transplantation: Risk Factors and Influence of the Immunosuppressive Drug Regimen

(2011) G.A. Spinelli et al.   TRANSPLANTATION PROCEEDINGS

mTOR inhibitor–associated proteinuria in kidney transplant recipients

(2011) Fritz Diekmann et al.   Transplantation Reviews

Assessment of erythropoiesis following renal transplantation

(2010) S. Beshara et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial

(2010) Markus Guba et al.   TRANSPLANTATION

Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study

(2009) Y. Lebranchu et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Immunosuppressive Drugs in Kidney Transplantation

(2009) Roberto Marcén   DRUGS

Posttransplant anemia: the role of sirolimus

(2009) Steven Fishbane et al.   KIDNEY INTERNATIONAL

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

(2009) Francesco P. Schena et al.   TRANSPLANTATION

Incidence and Risk Factors for Diarrhea Following Kidney Transplantation and Association With Graft Loss and Mortality

(2008) Suphamai Bunnapradist et al.   AMERICAN JOURNAL OF KIDNEY DISEASES